Analyst Ratings For Aratana Therapeutics (NASDAQ:PETX)
Today, Credit Suisse Group lowered its price target on Aratana Therapeutics (NASDAQ:PETX) to $8.00 per share.
Some recent analyst ratings include
- 3/12/2018-CL King Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 12/18/2017-Stifel Nicolaus Reiterated Rating of Hold.
- 2/9/2017-William Blair Reiterated Rating of Outperform.
Recent Insider Trading Activity For Aratana Therapeutics (NASDAQ:PETX)
Aratana Therapeutics (NASDAQ:PETX) has insider ownership of 5.20% and institutional ownership of 71.07%.
- On 1/30/2018 Peter Steven St, CEO, sold 19,367 with an average share price of $4.77 per share and the total transaction amounting to $92,380.59.
- On 1/11/2018 Craig A Tooman, Insider, sold 30,000 with an average share price of $5.27 per share and the total transaction amounting to $158,100.00.
- On 12/1/2017 Healthcare Master Fun Broadfin, Major Shareholder, sold 890,516 with an average share price of $5.70 per share and the total transaction amounting to $5,075,941.20.
- On 11/29/2017 Healthcare Master Fun Broadfin, Major Shareholder, sold 116,516 with an average share price of $6.53 per share and the total transaction amounting to $760,849.48.
- On 11/10/2017 Peter Steven St, Insider, sold 50,000 with an average share price of $7.00 per share and the total transaction amounting to $350,000.00.
- On 10/2/2017 Peter Steven St, Insider, sold 50,000 with an average share price of $6.24 per share and the total transaction amounting to $312,000.00.
- On 9/25/2017 Brent Standridge, COO, sold 10,000 with an average share price of $6.11 per share and the total transaction amounting to $61,100.00.
Recent Trading Activity for Aratana Therapeutics (NASDAQ:PETX)
Shares of Aratana Therapeutics closed the previous trading session at 4.12 up +0.09 2.23% with shares trading hands.